Clinical trials: Gene Mutation
Breast Cancer
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
This study will test any good and bad effects of combining the study drugs pembrolizumab and olaparib, given before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers.
- Trial name
- NCT05203445
- Testing
- Olaparib, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Long-Term Effects Secondary to Cancer Therapy
Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC
A Single-center, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC…
- Trial name
- NCT06356701
- Testing
- Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Breast Cancer, BRCA Mutation
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage
Tranexamic acid (TxA) is a drug that was approved by the FDA in 1986. It is an antifibrinolytic drug - this means that it is used to promote blood clotting by preventing the breakdown of blood clots that the participant's body…
- Trial name
- NCT05554211
- Testing
- Tranexamic acid, Normal saline
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwestern University
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc
Tuberous Sclerosis Complex
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Tuberous Sclerosis is a rare genetic disorder that affects about one in 15,000 individuals. It is part of the phacomatoses: a germline mutation of the gene Tuberous Sclerosis Complex 1 (TSC1) or TSC2 causes a protein dysfunction…
- Trial name
- NCT04112537
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Montpellier
Breast Cancer
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Previous studies have shown that the FGF signaling pathway is closely related to endocrine therapy resistance in breast cancer, but there is not sufficient evidence for the combination of endocrine therapy and FGFR inhibitors.
- Trial name
- NCT04936295
- Testing
- Fulvestrant plus Anlotinib
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Sun Yat-sen University
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
Acute Coronary Syndrome
Rehabilitation Exercise With MObile Technology and Education After Acute Coronary Syndrome
Despite a clear indication of grade Ia, cardiac rehabilitation (CR) is dramatically underutilized after acute coronary syndrome with less than 30% of patients addressed in France.
- Trial name
- REMOTE-ACS (NCT05385341)
- Testing
- Telerehabilitation (Tele RCV), Rehabilitation (RCV)
- Sponsor
- University Hospital, Toulouse
Urothelial Carcinoma, Bladder Cancer
Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma
Clinical trial to evaluate the performance characteristics(sensitivity and specificity) of AnchorDx's urine DNA methylation/somatic mutation profiling assay for detecting urothelial carcinoma compared to pathology in patients.
- Trial name
- NCT04314245
- Testing
- Active Comparator: Pathology, Active Comparator: Clinical Diagnosis, Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
- Where
- China
- Volunteers
- 1,170 people, healthy volunteers welcome
- Sponsor
- AnchorDx Medical Co., Ltd.
Multiple Sclerosis
Improving Hand Use in Multiple Sclerosis
This study will compare two different kinds of physical therapy to improve use of the hands in individuals with multiple sclerosis (MS).
- Trial name
- NCT01081275
- Testing
- CI Therapy, CAM treatments
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Multiple Sclerosis Society
Small Cell Lung Carcinoma
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of eligible patients diagnosed with BRAF V600E/K activating mutation-positive…
- Trial name
- NCT04507919
- Testing
- Dabrafenib, Trametininb
- Sponsor
- Novartis Pharmaceuticals
Non-small-cell Lung Cancer
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
This is a single-arm, open, multicenter phase II clinical study to evaluate the efficacy and safety of HL-085 capsules combined with Vemurafenib in the treatment of BRAF V600E mutated patients with unresectable locally advanced…
- Trial name
- NCT05900219
- Testing
- HL-085+Vemurafenib
- Volunteers
- 75 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Breast Cancer
Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development
To evaluate 1) the extent of patient overestimation of breast cancer development risk in subjects referred to a physician-based high-risk breast clinic; 2) the ability of physician counseling to improve patient risk perception…
- Trial name
- NCT00381927
- Testing
- Physician Counseling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Baystate Medical Center
Psychosis
COllaborative Shared Care to IMprove Psychosis Outcome
COSIMPO is a randomised controlled trial in which a collaborative shared care for psychosis implemented by complementary alternative providers (traditional and faith healers) and conventional primary health care providers (PHCP)…
- Trial name
- COSIMPO (NCT02895269)
- Testing
- Collaborative shared care
- Where
- 2 sites in Ghana, Nigeria
- Volunteers
- 307 people
- Sponsor
- University of Ibadan
Metastatic Non-small Cell Lung Cancer, BRAF V600 Mutation
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
This study aims to describe the treatment patterns in clinical practice in adult patients with mNSCLC with a BRAF V600E mutation.
- Trial name
- NCT05546905
- Where
- 39 sites in France, Germany and 3 more
- Volunteers
- 206 people
- Sponsor
- Pierre Fabre Medicament
Leukemia, Acute Myeloid (AML)
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who were refractory to or had relapsed after first-line…
- Trial name
- NCT02421939
- Testing
- gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 371 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Central Nervous System Tumor, Pediatric
Genetic Study of Brain Tumors in Young Children
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to understand how genes may be involved in the development of brain tumors in…
- Trial name
- NCT00010101
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pediatric Brain Tumor Consortium
Lung Cancer
Post-Treatment Surveillance in Lung Cancer
There are 13.7 million Americans currently living with a history of cancer. With continued improvements in cancer treatment and increasing life expectancy, this number is expected to reach nearly 18 million within the next…
- Trial name
- NCT03475420
- Volunteers
- 9,613 people
- Sponsor
- University of Virginia
Ventilation Therapy; Complications, Airway Clearance Impairment
In-line Mechanical Insufflation-Exsufflation in the Management of Ventilated Patients
Catheter suction (CS), the standard method for airway secretion management during mechanical ventilation, is invasive and has significant hemodynamic and traumatic side effects.
- Trial name
- NCT05365620
- Testing
- Mechanical In-Line Inexsufflation, catheter suction
- Volunteers
- 120 people
- Sponsor
- Alyn Pediatric & Adolescent Rehabilitation Hospital
Non Small Cell Lung Cancer
Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma
In non-small cell lung cancer and metastases in the pleural cavity, pathological effusion is formed. Currently, the most common and effective method of obliteration of the pleural cavity is pleurodesis with talcum powder.
- Trial name
- DPTA (NCT03827070)
- Testing
- Afatinib, Talcum powder
- Where
- Georgia
- Volunteers
- 12 people
- Sponsor
- Center Trials & Treatment Europe
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.